Alzheimers Disease Therapeutics Market Analysis North America,Europe,Asia,Rest of World (ROW) - US,Canada,UK,Germany,Japan - Size and Forecast 2024-2028

Alzheimers Disease Therapeutics Market Forecast 2024-2028

The Global Alzheimers Disease Therapeutics Market size is estimated to grow by USD 5.41 billion at a CAGR of 10.03% between 2023 and 2028. There has been an increasing awareness regarding Alzheimer's disease across the world. In addition, there are several initiatives to increase community awareness about the condition. For instance, the funded projects provided evidence-based and evidence-informed interventions and conducted extensive education, training, and outreach programs in various US communities. Moreover, there are several other Alzheimer's programs and public initiatives, such as the National Alzheimers Plan, AFA Teens, The Alzheimers Association Walk to End Alzheimers, and The Hampden Good Neighbor Program in the US. Hence, such factors are positively impacting the market.

What will be the size of the Alzheimer's Disease Therapeutics Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation by Distribution Channel, Drug Class and Geography Analysis

Technavio has segmented the market into Distribution Channel, Drug Class, and Geography

• The distribution channel segment is classified into hospital pharmacy, retail pharmacy, and e-commerce pharmacy
• The drug class segment is classified into cholinesterase inhibitors, n-methyl-d-aspartate receptor antagonist, and others
• The geography segment includes key regions such as North America, Europe, Asia, and the Rest of the World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.

Distribution Channel Analysis

Hospital pharmacy

The hospital pharmacy segment is estimated to witness significant growth during the forecast period. This segment is considered as the major distribution channel for Alzheimer's disease therapeutics owing to the large-scale requirements of such drugs for the treatment of patients. In addition, the increasing investment by the governments of several countries, such as India and China, to improve healthcare infrastructure will fuel the growth of this segment.

Get a glance at the market contribution of various segments Download PDF Sample

The hospital pharmacy segment was the largest segment and was valued at USD 3.55 billion in 2018. Moreover, the rapid growth in the number of hospitals in developing countries such as India and the rise in government initiatives to develop healthcare infrastructure has increased the demand. Therefore, the demand in hospitals is also increasing. In addition, the increasing number of cases of Alzheimer's disease will likely increase the adoption of therapeutics in hospitals worldwide.  Hence such factors are expected to propel the hospital segment, which is expected to fuel the growth of the hospital pharmacy segment of the market during the forecast period.

Drug Class Analysis

Cholinesterase inhibitors

The cholinesterase segment is an important therapeutic target for Alzheimer's disease. In addition, the deterioration of cholinergic neurons in the brain and the loss of neurotransmission are the major causes of the decline in cognitive functions in patients with Alzheimer's disease. Moreover, the main cause of Alzheimer's disease is also a reduction in acetylcholine synthesis. Hence, one of the possible therapeutic strategies is to increase the cholinergic levels in the brain by inhibiting the biological activity of acetylcholinesterase. Furthermore, as cholinesterase inhibitors increase the availability of acetylcholine in central synapses, it has now become the main approach to the symptomatic treatment of Alzheimer's disease. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period. 

N-methyl-D-aspartate receptor antagonist

One of the only approved N-methyl-D-aspartate receptor antagonists for the symptomatic treatment of moderate-to-severe Alzheimer's disease is Memantine. In addition, it possesses a three-ring structure with a bridgehead amine. Under physiological conditions, it carries a positive charge that binds at the Mg2+ site within the N-methyl-D-aspartate receptor-associated channel. Moreover, according to clinical trial results, memantine can achieve its pharmacological actions and does not show the adverse effects typically associated with high-affinity NMDA blockers. Furthermore, memantine has exhibited efficacy and safety in placebo-controlled trials in patients with moderate-to-severe Alzheimer's disease. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America holds the major share, primarily due to the increasing awareness of the disease and its strong prevalence of Alzheimer's disease. In addition, the prevalence of the disease has been increasing at a significant rate in the developed countries of the region. Moreover, the prevalence of Alzheimer's disease and other dementias is also high in Canada. For instance, In 2011, 2.23% of the total population of Canada was affected by Alzheimer's disease and other dementias. In addition, this percentage is expected to increase to 3.45% by 2031. Hence, such factors are driving the market growth in North America during the forecast period.

Buy Full Report Now

Key Alzheimer's Disease Therapeutics Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AB Science SA: The company offers alzheimer disease therapeutics such as Masitinib.

• AbbVie Inc.
• AgeneBio Inc.
• Biogen Inc.
• Cipla Ltd.
• Curasia Medilab
• Denali Therapeutics Inc.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• Grifols SA
• H Lundbeck AS
• Johnson and Johnson
• Lifecare Neuro Products Ltd.
• Lupin Ltd.
• Novartis AG
• Pfizer Inc.
• Psycogen Captab
• Solco Healthcare
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market is witnessing notable advancements in the field of biological therapies and amyloid beta inhibitors aimed at addressing neurodegenerative diseases. Alzheimer's disease, affecting both women and men, poses significant challenges, impacting life expectancy and cognitive function. As the prevalence of Alzheimer's and related dementias rises, there's an increasing demand for innovative therapies. Clinics and hospitals play a crucial role in providing diagnosis and treatment, often utilizing cognitive assessment systems to evaluate patients. With a growing population of Medicare beneficiaries affected by Alzheimer's, the need for effective therapeutics is pressing. These therapies target various symptoms such as memory impairment, impaired thinking, and behavioral changes, aiming to improve brain cell function and everyday tasks. Heightened awareness and consciousness of Alzheimer's disease drive research and development efforts in the quest for effective treatments.

Key Market Drivers

The market is experiencing significant growth, driven by the availability and ongoing research and development of novel biomarkers. Alzheimer's disease, a neurodegenerative disorder characterized by the formation of B-amyloid plaques and neurofibrillary masses in the brain parenchyma, results in progressive memory loss. The prevalence of Alzheimer's disease has surged globally, underscoring the urgent need for new therapies. Biomarkers, including blood tests, cerebral spinal fluid analysis, and neuroimaging scans such as PET and MRI, play a pivotal role in drug development by aiding in the identification and testing of disease-modifying therapies. As efforts intensify to identify effective treatments for Alzheimer's disease, fueled by advancements in biomarker research, the market is poised for substantial growth in the forecast period.

Significant Market Trends

A key factor shaping the market growth is the increasing funding for therapeutics discovery. The rising prevalence of Alzheimer's disease has led to an increase in demand for its therapeutics, as well as garnered significant funding for the development of therapeutics. In addition, over the past years, different organizations and governments globally have been investing in therapeutics for Alzheimer's disease, which has resulted in scientific achievements that have benefited many people with Alzheimer's disease globally.

Moreover, the Federal Government of the US is the largest public funder of research and development of therapeutics for Alzheimer's disease. In addition, organizations such as The National Institute on Aging, the National Center for Advancing Translational Science, the National Institute of General Medical Sciences, and the National Institute of Mental Health grant funds for research on drug development for Alzheimer's disease. Hence, such factors are driving the market growth during the forecast period.

Major Market Challenges

Issues associated with the diagnosis of Alzheimer's disease are one of the key challenges hindering the market growth. It is still a clinical challenge to determine Alzheimer's disease at an early stage. In addition, the neuropathological changes in Alzheimer's disease start to accumulate in the brain 10-15 years before the first sign of clinical impairment.

Moreover, dementia due to Alzheimer's disease is the last stage of the disease. In addition, the major limitation of the current approaches is that the number of useful markers for every stage of the disease is less. Furthermore,  markers for brain atrophy have been developed, but the condition is not always present at the early diagnosis of Alzheimer's disease. Hence, such factors are hindering the market growth during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Distribution Channel Outlook
  • Hospital pharmacy
  • Retail pharmacy
  • E-commerce pharmacy
• Drug Class Outlook
  • Cholinesterase inhibitors
  • N-methyl-D-aspartate receptor antagonist
  • Others
• Geography Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of the World (ROW)
    • Australia
    • Argentina
    • Brazil

Market Analyst Overview

The market is witnessing significant advancements in treatment, with the development of biological therapies and drug discovery techniques targeting brain cells and central nervous system disorders. Amyloid beta inhibitors like Crenezumab and Tau antibodies are promising pipeline drugs in the fight against neurodegenerative diseases. Medications such as Aricept, Exelon, and Razadyne aim to improve cognitive function and behavioral skills in diagnosed patients. With an aging population and increasing awareness, there's a growing consciousness of the disease's impact, leading to a rise in the prescription rate. Furthermore, the availability of e-commerce platforms and online pharmacies facilitates access to medications for patients and caregivers, enhancing convenience in managing everyday tasks. Despite challenges, advancements in treatment offer hope for improving life expectancy and reducing disability and deaths among Medicare beneficiaries affected by Alzheimer's Disease.

Moreover, the market addresses the urgent need for effective treatments for this debilitating central nervous system disorder. With the prevalence of Alzheimer's disease rising, there's a growing consciousness of the disease and its impact on individuals, families, and healthcare systems. Pharmaceutical companies are investing heavily in research and development to combat memory impairment and cognitive decline associated with Alzheimer's. Cognitive assessment systems aid in diagnosis, while therapies targeting N-methyl D-aspartate antagonist receptors and Tau antibodies show promise in slowing disease progression. With the advent of online pharmacies and e-commerce platforms, access to Alzheimer's therapeutics has become more convenient, benefiting both men and women affected by the disease. As research continues and social skills are prioritized, the Alzheimer's therapeutics market is poised for significant growth in the coming years.

The market is witnessing notable growth, driven by the increasing demand for innovative treatments in drug stores & retail pharmacies and the expanding reach of e-commerce platforms. With the rise of e-commerce services, patients have easier access to medications through online pharmacies. The Internet serves as a crucial tool for disseminating information about Alzheimer's disease therapies, with platforms like the NCBI providing valuable research insights. Organizations like the Pan American Health Organization play a vital role in raising awareness and providing support. Additionally, advancements in smartphone technology enable convenient monitoring and management of the disease. Emerging treatments like tau antibody therapies are revolutionizing Alzheimer's treatment paradigms. With ongoing research and innovative thinking, the Alzheimer's disease therapeutics market is poised for significant expansion.

Alzheimer's Disease Therapeutics Market Scope
Report Coverage	Details
Page number	168
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 10.03%
Market Growth 2024-2028	USD 5.41 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	8.83
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 39%
Key countries	US, Canada, UK, Germany, and Japan
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	AB Science SA, AbbVie Inc., AgeneBio Inc., Biogen Inc., Cipla Ltd., Curasia Medilab, Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson, Lifecare Neuro Products Ltd., Lupin Ltd., Novartis AG, Pfizer Inc., Psycogen Captab, Solco Healthcare, Teva Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.
Market dynamics	Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about vendors
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch